Caremark unit delays adding the company's new HIV prevention drug Yeztugo over pricing concerns. Read more here.

HBcAb-positive, HBsAg-negative people with HIV can safely switch from tenofovir-containing ART without clinically significant HBV reactivation.

A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...

New HIV/AIDS clinic opens in Whitehaven AIDS Healthcare Foundation ... Jack Armstrong covers breaking news and the ...

How much time behind bars is too much time? How harsh should speeding penalties be? When should someone be charged for passing an infection to another, and how best to honor a slain parole officer?

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Today, a diagnosis with human immunodeficiency virus (HIV) is not as dire as it was 40 years ago. Thanks ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating—and possibly even curing—the disease a seemingly insurmountable obstacle to achieve. But ...

Public-health experts and HIV activists said they were concerned about the potential for further damage from cuts to federal health-care funding this year after the city’s Department of Public Health ...

New research based on adults who were cured of HIV after stem cell transplants may offer hope to ultimately have a global impact on HIV care. A total of 10 individuals with HIV have been cured to date ...

Generic versions of a groundbreaking injectable HIV-prevention drug should be available for $40 a year in more than 100 countries from 2027, Unitaid and the Gates Foundation said Wednesday. The two ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...